{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:55:58Z","timestamp":1761843358781},"reference-count":18,"publisher":"Wiley","issue":"s4","license":[{"start":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T00:00:00Z","timestamp":1094169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The clinical management of Crohn's disease can be considered in relation to the treatment of acute disease and the maintenance of remission. The medication used to achieve these two goals may or may not be the same. Some patients with mildly active disease may respond to high\u2010dose (4\u2003g\/day) mesalazine (mesalamine), and 5\u2010aminosalicylic acid may also be helpful in weaning a patient off steroids after treatment for a flare\u2010up. However, the value of 5\u2010aminosalicylic acid in maintaining remission in Crohn's disease remains controversial. Subgroups of patients may be helped: for example, patients with Crohn's disease who have experienced a relapse within the last 2\u2003years may benefit. Steroids form the first\u2010line therapy for acute episodes of inflammation but do not maintain remission. Azathioprine and mercaptopurine are the first\u2010line drugs for the maintenance of remission in moderate to severe Crohn's disease, and by titrating the dose up from 2\u2003mg\/kg daily, some previously resistant patients will be brought into remission. One\u2010half of patients who do not tolerate azathioprine will tolerate mercaptopurine. Methotrexate is effective in inducing and maintaining remission, and is useful for patients who fail azathioprine treatment. Thalidomide is not proven in controlled studies, but two open studies have demonstrated its efficacy. The optimal dose, however, remains to be defined. Purified liquid diets with food exclusion can induce remission in patients with active disease, but food exclusion is difficult to maintain long term. Infliximab can induce and maintain remission in patients resistant to other therapies, with two\u2010thirds of patients initially responding to treatment. One\u2010third go into remission and, of those who respond to a single treatment, approximately one\u2010half maintain remission when treated regularly for a year. Infliximab is, however, associated with an increased risk of infection, and its effect on cancer incidence is uncertain. The development of antibodies against the drug is associated with a loss of effect and allergic infusion reactions. In summary, simple proven therapies should be used first, because of their safety and benefit in some patients. However, aggressive therapy should be used when needed.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02052.x","type":"journal-article","created":{"date-parts":[[2004,12,19]],"date-time":"2004-12-19T10:07:16Z","timestamp":1103450836000},"page":"102-105","source":"Crossref","is-referenced-by-count":9,"title":["Chronic active disease and maintaining remission in Crohn's disease"],"prefix":"10.1111","volume":"20","author":[{"given":"M. A.","family":"Kamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9,3]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90337-C"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8608877"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90411-5"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90385-8"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91725-J"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.1.82"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92150-4"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01683.x"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00938-7"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320503"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422202"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03287.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70276-3"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02052.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02052.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02052.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:27:56Z","timestamp":1695814076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02052.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,3]]},"references-count":18,"journal-issue":{"issue":"s4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02052.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02052.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,3]]}}}